36th week of 2019 patent applcation highlights part 18 |
Patent application number | Title | Published |
20190270764 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE - Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags. | 2019-09-05 |
20190270765 | Polymerizable Compound, Compound, and Method for Producing Boranophosphate Oligomer - Provided a polymerizable compound represented by the following Formula A-1 or Formula A-2: In Formula A-1 or Formula A-2, R | 2019-09-05 |
20190270766 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS - Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form | 2019-09-05 |
20190270767 | OXYSTEROL-THERAPEUTIC AGENT DERIVATIVE FOR BONE HEALING - Oxysterol-therapeutic agent derivatives or OXY133-therapeutic agent derivative compounds and methods of synthesizing the same are provided for use in promoting osteogenesis, osteoinduction and/or osteoconduction. Methods of synthesizing in a single container OXY133-therapeutic agent derivatives having high yields and improved process safety are also provided. Methods for synthesizing OXY133-therapeutic agent derivatives that are stereoselective are also provided. | 2019-09-05 |
20190270768 | PROCESS FOR THE SYNTHESIS OF AMIDE BONDS WITH THE AID OF NOVEL CATALYSTS - The invention relates to a process for the production of amide bonds, in particular peptide bonds, with the aid of novel amide linking reagents containing an anion of the formula (I), to the novel reagents, and to the preparation thereof. | 2019-09-05 |
20190270769 | METHODS FOR ANTIBODY DRUG CONJUGATION, PURIFICATION, AND FORMULATION - Methods of producing, purifying, and formulating antibody drug conjugates (ADCs) are provided herein. The methods use continuous conjugation processes, single-pass tangential flow filtration, countercurrent diafiltration, and/or in-line process automation technologies. The methods decrease process times and costs and improve product consistency. | 2019-09-05 |
20190270770 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION - The present invention relates to the use of dipeptidyl ketoamide compounds for preventing accumulation of triglycerides in adipose tissue or for reducing the amount of triglycerides in adipose tissue in a subject in need thereof and to novel dipeptidyl ketoamide compounds. | 2019-09-05 |
20190270771 | PEPTIDES DERIVED FROM THE PROPEPTIDE NTSR3 AND THEIR USE IN THE TREATMENT OF DEPRESSION - Disclosed are new peptides derived from the neurotensin receptor 3 (NTSR3), and to their use, particularly in the treatment of various diseases, especially depression. | 2019-09-05 |
20190270772 | PEPTIDE WITH ANTI-OBESITY AND ANTI-DIABETES ACTIVITY AND USE THEREOF - A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs. | 2019-09-05 |
20190270773 | PEPTIDE WITH ANTI-OBESITY AND ANTI-DIABETES ACTIVITY AND USE THEREOF - A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs. | 2019-09-05 |
20190270774 | PEPTIDE WITH ANTI-OBESITY AND ANTI-DIABETES ACTIVITY AND USE THEREOF - A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs. | 2019-09-05 |
20190270775 | POLYPEPTIDE AND USE THEREOF - Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis. | 2019-09-05 |
20190270776 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same. | 2019-09-05 |
20190270777 | ENGINEERING THE PRODUCTION OF A CONFORMATIONAL VARIANT OF OCCIDIOFUNGIN THAT HAS ENHANCED INHIBITORY ACTIVITY AGAINST FUNGAL SPECIES - Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar activity. This invention is directed to compositions enriched for particular occidiofungin diastereomers/conformers, methods of making compositions enriched for particular diastereomers/conformers and microorganisms suitable for producing enriched compositions of particular diastereomers/conformers. Methods of treating fungal infections or plants infected by fungi are also provided. | 2019-09-05 |
20190270778 | Cyclic Peptides As C5a Receptor Antagonists - The invention relates to cyclic peptide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to cyclic peptide C5a receptor antagonists of formula (Ia) or formula (Ib), or pharmaceutically acceptable salts thereof, wherein R | 2019-09-05 |
20190270779 | Re-Directed Immunotherapy - The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. | 2019-09-05 |
20190270780 | BROAD SPECTRUM INSECTICIDAL POLYPEPTIDE AGAINST LEPIDOPTERAN PESTS AND METHODS OF USE THEREOF - The disclosure provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2019-09-05 |
20190270781 | TREATMENT OF ISCHEMIA - A system, including methods and compositions, for treatment of ischemia. | 2019-09-05 |
20190270782 | OVEREXPRESSION OF FOXC1 TO TREAT CORNEAL VASCULARIZATION - Disclosed are methods and pharmaceutical compositions for treating and inhibiting conical vascularization including conical vascularization associated with viral infection, chemical injury, autoimmune conditions, and post-corneal transplantation or in subjects having a PAX6 mutation associated with conical vascularization. The methods and pharmaceutical compositions are utilized in administering treatment that results in increased concentration of FOXC1 in a subject's cornea in order to treat or inhibit corneal vascularization. | 2019-09-05 |
20190270783 | PRODUCTION OF RECOMBINANT LUBRICIN - Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production. | 2019-09-05 |
20190270784 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-09-05 |
20190270785 | MUSCLIN PEPTIDES AND METHODS OF USE THEREOF - In certain embodiments, the present invention provides a musclin peptide and methods of increasing muscle growth, performance, resistance to injury and/or preventing or reducing muscle atrophy and improving overall skeletal muscle, metabolic and cardiac health in an animal in need thereof by administering a musclin peptide. | 2019-09-05 |
20190270786 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES - The present invention provides novel peptide inhibitors of interleukin-23, and related methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn's disease and psoriasis. | 2019-09-05 |
20190270787 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF - Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications. | 2019-09-05 |
20190270788 | CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS - The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide. | 2019-09-05 |
20190270789 | GLUCAGON-GLP-1-GIP TRIPLE AGONIST COMPOUNDS - The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders. | 2019-09-05 |
20190270790 | THERAPEUTIC FOR THE PREVENTION AND/OR TREATMENT OF WEIGHT GAIN AND/OR DIABETES - Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat. | 2019-09-05 |
20190270791 | PLATELET TARGETED TREATMENT - The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets. | 2019-09-05 |
20190270792 | Biological Therapeutics for Infection-Relating Disorders or Conditions - The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens. | 2019-09-05 |
20190270793 | Anti-PHF-Tau Antibodies and Uses Thereof - Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples. | 2019-09-05 |
20190270794 | ANTI-APOE ANTIBODIES - The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human. | 2019-09-05 |
20190270795 | REP PROTEIN AS PROTEIN ANTIGEN FOR USE IN DIAGNOSTIC ASSAYS - The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in a sample from a subject as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is a MSBI1 Rep or MSBI2 Rep. | 2019-09-05 |
20190270796 | THERAPEUTIC AGENT FOR PERIODONTITIS AND COMPOSTION FOR TREATING PERIODONTITIS - The present invention provides a therapeutic agent for periodontitis including: a hepatocyte growth factor (HGF) signal inhibitor as an active ingredient. | 2019-09-05 |
20190270797 | CREBBP RELATED CANCER THERAPY - The present disclosure provides novel cancer therapies. The treatment of cancers harboring EP300 mutations with CREBBP inhibition therapy is described. | 2019-09-05 |
20190270798 | METHODS AND COMPOSITIONS FOR MODULATON OF TRANSFORMING GROWTH FACTOR BETA-REGULATED FUNCTIONS - Disclosed are compositions and methods for modulating the activity of TGF-β. More particularly, compositions and methods for modulating the release of active TGF-β from an LRRC33-TGF-β prodomain-TGFβ ternary complex are provided, as are and methods of treatment based upon such modulation. | 2019-09-05 |
20190270799 | RGMa BINDING PROTEIN AND USE THEREOF - The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG. | 2019-09-05 |
20190270800 | PRODUCTION CELL LINE ENHANCERS - The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture. | 2019-09-05 |
20190270801 | Oral Composition of Anti-TNF-Alpha Antibodies - The present application relates to a pharmaceutical composition for oral administration, comprising a monoclonal anti-tumor necrosis factor alpha antibody (TNFα) and at least one or more pharmaceutically acceptable excipients selected from the group comprising: a carboxymethyl-dextran, a chitosan, a cyclodextrin, or a combination of same, as well as the use of said composition in the treatment of inflammatory diseases or autoimmune diseases. | 2019-09-05 |
20190270802 | TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 ANTAGONIST - The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an antagonist of IL-27, and the use of the combination therapies for the treatment of cancer. In certain embodiments, the PD-1 antagonist is an anti-human PD-1 antibody, or antigen binding fragment thereof. In further embodiments, the anti-PD-1 antibody is pembrolizumab. In certain embodiments the antagonist of IL-27 is an anti-IL-27 antibody, or antigen binding fragment thereof, an anti-p28 antibody, or antigen binding fragment thereof, or an anti-EBI-3 antibody, or antigen binding fragment thereof. Also provided are medicaments, compositions, and kits comprising a PD-1 antagonist and an IL-27 antagonist for use in treating cancer. | 2019-09-05 |
20190270803 | USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS - Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists. | 2019-09-05 |
20190270804 | IL-17 ANTAGONISTIC ANTIBODIES - An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis. | 2019-09-05 |
20190270805 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2019-09-05 |
20190270806 | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF - The present invention provides antagonizing antibodies that bind to IL-6, fusion proteins thereof with VEGF Trap, and conjugates of either thereof, and methods of using same. The anti-IL-6 antibodies can be used therapeutically alone or in combination with other therapeutics to diseases. | 2019-09-05 |
20190270807 | USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA - This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof | 2019-09-05 |
20190270808 | TREATMENT OF DISEASES RELATED TO IGFB3 AND ITS RECEPTOR - Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided. | 2019-09-05 |
20190270809 | HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE THEREOF - The present disclosure provides a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region (V | 2019-09-05 |
20190270810 | OPTIMIZED ANTIBODY VARIABLE REGIONS - The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 2019-09-05 |
20190270811 | ANTIBODIES SPECIFIC TO FCRN - The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA. | 2019-09-05 |
20190270812 | COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER - The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treat-ment of cancer, and in particular for treating cancers that express PD-L 1. | 2019-09-05 |
20190270813 | Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof - The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease. | 2019-09-05 |
20190270814 | BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE - The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules. | 2019-09-05 |
20190270815 | NOVEL ANTI-PD-1 ANTIBODIES - The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which an block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function. | 2019-09-05 |
20190270816 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS - The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies. | 2019-09-05 |
20190270817 | Anti-PD-1 Antibodies and Methods of Treatment - Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided. | 2019-09-05 |
20190270818 | PD-1 AGONIST ANTIBODIES AND USES THEREOF - The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues. | 2019-09-05 |
20190270819 | INTEGRIN ALPHA 9 BLOCKADE SUPPRESSES LYMPHATIC VALVE FORMATION AND PROMOTES TRANSPLANT SURVIVAL - In certain embodiments, the present invention provides methods of suppressing valvulogenesis (VG) in a lymphatic vessel in an inflamed or transplanted tissue or organ in a mammal in need thereof comprising administering an effective amount of an anti-integrin alpha 9 (Itga-9) therapeutic agent to the mammal, and optionally by administering VEGFR-3. | 2019-09-05 |
20190270820 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE - The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods. | 2019-09-05 |
20190270821 | EPHA3 ANTIBODIES FOR THE TREATMENT OF PULMONARY FIBROSIS - The invention provides methods of treating or preventing pulmonary fibrosis or idiopathic pulmonary fibrosis (IPF) by administering an anti-EphA3 antibody to a patient. Moreover, the invention provides methods of identifying a candidate for treatment with an anti-EphA3 antibody by evaluating BAL fluid for EphA3 positivity are also disclosed. The invention further provides methods of measuring the efficacy of treatment by evaluating the reduction of the disease markers of fibrosis in a pulmonary fibrosis or IPF patient treated with an anti-EphA3 antibody are also disclosed. | 2019-09-05 |
20190270822 | ANTIBODY-CONJUGATED NANOPARTICLES AND MEDICAL USES THEREOF - An antibody-conjugated nanoparticle, 50 to 1000 nm in size, containing an anti-Mullerian hormone receptor II (AMHRII) antibody that is conjugated to a nanocomplex formed of a lipid-based delivery agent and a cytotoxin, the delivery agent and the cytotoxin being non-covalently bonded to each other. Also disclosed are a method of preparing such an antibody-conjugated nanoparticle and use thereof for inducing sterilization in a subject and for treating an AMHRII-associated condition. | 2019-09-05 |
20190270823 | ANTIBODIES TO CD70 - The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth. | 2019-09-05 |
20190270824 | METHOD FOR TREATING JOINT DAMAGE - Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods. | 2019-09-05 |
20190270825 | METHODS AND COMPOSITIONS FOR REDUCING CARDIAC DAMAGE AND OTHER CONDITIONS - Endoglin has been identified to play a functional role as a regulator of TGFβ1 signaling, particular in TGFβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGFβ1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity. | 2019-09-05 |
20190270826 | ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF - Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multi specific antibodies against IL1RAP and CD3 described herein. | 2019-09-05 |
20190270827 | PASSIVE IMMUNIZATION FOR STAPHYLOCOCCUS INFECTIONS - Disclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to a | 2019-09-05 |
20190270828 | TANDEM ANTIBODIES - This document provides methods and materials related to self-masking tandem antibodies, for example, Self-Masking Anti-tumoR Tandem antibody (SMART-body). For instance, a self-masking tandem antibody may contain two antibody-based domains (each of which contains an antigen-binding site) that are connected by a linker peptide cleavable by a protease, and the connection between the two antibody-based domains results in the masking of at least one of the antigen-binding sites. In some embodiments, for example, the SMART-body is first provided as a single molecule which does not bind antigens because of the masking of the antigen-binding sites within the molecule, but subsequently, the linker peptide is cleaved by a protease expressed in a tumor microenvironment, severing the connection between and removing the masking of the two antibody-based domains, which can then bind antigens expressed in the tumor, achieving localized, targeted cancer therapy. | 2019-09-05 |
20190270829 | Method for Preparing Cross-Linked Hyaluronic Acid-Based Cell Scaffold Material - Disclosed is a method for preparing cross-linked hyaluronic acid-based cell scaffold material. The hyaluronic acid-based cell scaffold is obtained by subjecting a hyaluronic acid and a disulfide cross-linking agent to an amidation reaction, followed by dialysis-freeze drying. The cell scaffold has abundant pores, good mechanical strength which ensures that the scaffold does not rupture in transplantation, and good biocompatibility. The method is advantageous in that the raw material is easy to obtain, the reaction condition is moderate, and the process is simple. Cross-linked networks of the prepared hydrogel contain disulfide bonds, which can quickly split into single chains at the presence of small molecular glutathione. The hyaluronic acid-based cell scaffold has flexibly controllable mechanical property, disaggregation ability, and swelling property, and therefore has wide applications in facilitating cartilage injury repair, skin repair, cell culture, etc. | 2019-09-05 |
20190270830 | METHOD FOR SEPARATING HYDROCARBONS FROM POLYMER - The present invention is directed to a process for separating an olefm copolymer from volatile gases using a flash separator. The flash separator can be used with a solution or high pressure process. The mass transport of volatile gases from the viscous polymer melt is increased. | 2019-09-05 |
20190270831 | NON-PHTHALATE DONOR FOR POLYOLEFIN CATALYSTS - A solid catalyst component for use in olefinic polymerization, includes titanium, magnesium, a halogen, and an internal electron donor compound; wherein: the internal electron donor compound is at least one compound represented by Formula (I)). | 2019-09-05 |
20190270832 | PROCESS FOR PREPARING CONJUGATED DIENE (CO)POLYMERS IN THE PRESENCE OF A CATALYTIC SYSTEM COMPRISING A PYRIDYL IRON (III) COMPLEX - A process for preparing conjugated diene (co)polymers comprising polymerizing at least one conjugated diene in the presence of a catalytic system comprising: (a) at least one pyridyl iron (III) complex having general formula (I) or (II): wherein: —R | 2019-09-05 |
20190270833 | POLYOLEFIN CATALYST AND METHOD FOR PREPARING POLYOLEFIN BY USING SAME - Disclosed are a catalyst having a high molecular weight by using a novel metallocene catalyst; a method for preparing a polyolefin by using the same; and a method for preparing an ethylene-propylene random copolymer having a high molecular weight and ethylene syndiotactic index and having a small crystal size, thereby having improved transparency during injection. The present invention provides a transition metal compound represented by chemical formula 1. | 2019-09-05 |
20190270834 | Polymerizable Composition for Optical Articles - A polymerizable composition includes the reaction product of an isohexide bischloroformate, at least one polyol, allyl alcohol, and, optionally, at least one polychloroformate. An exemplary polymerizable composition includes the transesterification reaction product of (a) an isohexide, diallyl carbonate, and at least one polyol; and (b) organic peroxide. A polymerizate including the polymerizable composition and an optical article including the polymerizable composition are also provided. | 2019-09-05 |
20190270835 | CROSSLINKING AGENT AND FLUORINE-CONTAINING AROMATIC COMPOUND - A composition includes a fluoroelastomer, a crosslinking initiator, and a crosslinking agent. The crosslinking agent comprises a compound that comprises two or more structures represented by a formula (3), | 2019-09-05 |
20190270836 | METHOD OF PREPARING HIGH SOLIDS CONTENT POLYMER POLYOLS HAVING LOW VISCOSITY - Provided is a method of preparing a polymer polyol, including steps of: (a) polymerizing a polyol and a monomer in presence of a diluent to prepare a primary particle dispersed liquid; and (b) feeding an additional polyol and monomer into the primary particle dispersed liquid and polymerizing to prepare a secondary particle dispersed liquid. | 2019-09-05 |
20190270837 | POLYCARBODIIMIDE COPOLYMER - To provide a polycarbodiimide copolymer and a modified polycarbodiimide copolymer each suitable for a curing agent that can allow a cured product of a carboxy group-containing resin composition to be improved in flexibility without any loss of water resistance, as well as a curing agent of a carboxy group-containing resin composition, and a carboxy group-containing resin composition. The present invention enables a cured product to be enhanced in water resistance due to introduction of a predetermined soft segment into a polycarbodiimide molecule, in use for a curing agent, and also enables a carboxy group-containing resin composition to be enhanced in storage stability due to modification with an aliphatic amine or an aromatic heterocyclic amine. | 2019-09-05 |
20190270838 | Low-Viscosity, Rapid Curing Laminating Adhesive Composition - The invention relates to a 2-component polyurethane adhesive, in particular for laminating films, wherein the PU adhesive, based on the total weight of the laminating adhesive composition, (a) contains as resin component at least one NCO-terminated polyurethane pre-polymer having a content of at least 40% by weight of diphenylmethandiisocyanate (MDI), wherein the MDI is 4,4′-diphenylmethandiisocyanate or a mixture thereof with 2,4′-diphenylmethandiisocyanate, and (b) contains as hardener component a polyol mixture comprising at least three different polyols. The invention further relates to the use of the adhesive for adhesively bonding films, to methods for producing composite films, and to composite films bonded by means of the described adhesive. | 2019-09-05 |
20190270839 | PREPARATION OF RETORT PACKAGING INK THROUGH INCORPORATION OF POLYETHYLENE GLYCOL INTO POLYURETHANE RESINS - A method of preparing a retort packaging article includes: includes applying an ink to an outer surface of a sealable packaging and overlaying a substantially transparent lamination layer over the ink to envelope at least a portion of the sealable packaging. The ink includes a binder that includes a polyurethane resin that contains an elastomer which is a reaction product of a polyol and polyalkylene glycol with an isocyanate. The elastomer may be chain extended with a diamine or a diol. | 2019-09-05 |
20190270840 | THERMOPLASTIC POLYURETHANES WITH REDUCED TACKINESS - The present invention relates to novel thermoplastic polyurethane (TPU) compositions that have crystalline chain ends. The TPU compositions of the invention can provide improved resiliency, lower surface free energy, and/or reduced stickiness, while maintaining other desirable physical properties. The TPU compositions of the present invention are made from the reaction product of an aliphatic polyisocyanate, a polycaprolactone polyester polyol, an optional chain extender component, and a chain terminator component, which comprises a short chain crystalline compound containing a single functional group capable of terminating the chain of the thermoplastic polyurethane. | 2019-09-05 |
20190270841 | LOW-DAMPING POLYURETHANE ELASTOMER - The present invention relates to a method of preparing a polyurethane elastomer. The method includes a step of reacting at least one isocyanate composition and one polyol composition containing a poly-ε-caprolactone polyol obtained by reacting ε caprolactone and a diol having a number average molecular weight of from 80 to 1500 g/mol to obtain an isocyanate-functional prepolymer; and a step of reacting the prepolymer with at least one chain extender. The polyol composition contains α-hydro-ω-hydroxypoly(oxytetramethylene) polyols in an amount ranging from 0 to 1 wt % based on the entire polyol composition. The present invention further relates to a polyurethane elastomer prepared by such a method and also to the use of the polyurethane elastomer in the manufacture of a shaped article, especially a damping element, a shock absorber, a stop buffer, or a part of a shoe, such as a shoe sole, in particular, an insert sole or a midsole. | 2019-09-05 |
20190270842 | TDI BASED LOW-VISCOSITY POLYISOCYANATES WITH ISOCYANURATE GROUPS - The invention relates to a polyisocyanate which is based on tolylene 2,4-diisocyanate, tolylene 2,6-diisocyanate or a mixture of tolylene 2,4- and 2,6-diisocyanate and has isocyanurate groups, wherein the polyisocyanate has
| 2019-09-05 |
20190270843 | TDI BASED POLYISOCYANATE MIXTURE WITH A HIGH SOLIDS CONTENT - The invention relates to a polyisocyanate mixture comprising at least one polyisocyanurate which is based on tolylene diisocyanate and has isocyanate groups and at least one polyurethane which is based on tolylene diisocyanate and has isocyanate groups, wherein the polyisocyanate mixture has | 2019-09-05 |
20190270844 | HOMOGENEOUS AMORPHOUS HIGH HEAT EPOXY BLEND COMPOSITE COMPOSITIONS, ARTICLES, AND USES THEREOF - A high heat epoxy prepreg, comprising a substrate; a high heat epoxy composition comprising: a hardener; a high heat epoxy mixture comprising: a high heat epoxy compound and an auxiliary epoxy compound different from the high heat epoxy compound; wherein the high heat epoxy mixture has a glass transition temperature between −10 C and 62 C, wherein the prepreg comprises 40 to 80 volume % substrate, and 60 to 20 volume % of the high heat epoxy composition, wherein the prepreg comprises 12 to 45 volume % of the high heat epoxy compound; wherein the high heat epoxy composition comprises 50 to 75 wt % of the high heat epoxy compound; and a cured, laminated sample of the prepreg has a maximum tensile stress of 800 MPa or greater, measured as per ASTM D 3039, and a modulus of 70 GPa or greater measured as per ASTM D 3039; and a cured sample of the high heat epoxy composition has a glass transition temperature greater than 200 C. | 2019-09-05 |
20190270845 | COPOLYMER, A METHOD OF SYNTHESIZING THEREOF, AND A METHOD FOR PRODUCING HYDROGEN GAS - A copolymer containing carbazole-based and vinylene based moieties, a photoelectrode comprising a metal oxide substrate and the copolymer as a photoelectrocatalyst component to the photoelectrode, as well as a photoelectrochemical cell including the photoelectrode. Methods of producing the copolymers, and methods of using the photoelectrochemical cell to produce hydrogen gas are also provided. | 2019-09-05 |
20190270846 | POLYARYLATE RESIN AND ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER - A polyarylate resin is represented by general formula (1) shown below. In general formula (1), R | 2019-09-05 |
20190270847 | METHODS OF FORMING DYNAMIC CROSS-LINKED POLYMER COMPOSITIONS USING FUNCTIONAL CHAIN EXTENDERS UNDER BATCH PROCESS - Provided herein are methods for preparing dynamic cross-linked polymer compositions derived from an ester oligomer component, a chain extender component, and one or more of a transesterification or poly condensation catalyst are described. The dynamic cross-linked polymer compositions may be prepared via melt poly condensation. | 2019-09-05 |
20190270848 | METHOD FOR PURIFYING BIODEGRADABLE POLYMERS - The present disclosure relates to a process for obtaining an ultrapure polymer by simply and effectively removing unreacted residual monomer in polymer, which is generated during production of a biodegradable polymer such as polylactic acid or derivatives thereof. | 2019-09-05 |
20190270849 | END MODIFIED POLYAMIDE RESIN - A terminally modified polyamide resin has a terminal structure represented by general formula (I), wherein the terminal structure represented by general formula (I) is contained at a quantity of 1-10 mass % relative to 100 mass % of the terminally modified polyamide resin, the weight average molecular weight/content [mass %] ratio of the terminal structure represented by general formula (I) is 6,000-20,000, and the melt viscosity at a temperature corresponding to melting point+60° C. and at a shear rate of 9728 sec | 2019-09-05 |
20190270850 | SULFUR-CONTAINING POLYMERIC PARTICLES AND COMPOSITIONS - Sulfur-containing polymeric particles having a high sulfur content can be prepared using emulsion polymerization. The sulfur-containing polymeric particles are useful in aerospace coatings and sealants. | 2019-09-05 |
20190270851 | METHOD FOR PRODUCING SIOH-FUNCTIONAL POLYSILOXANES - High hydroxyl-content organopolysiloxanes of low molecular weight are prepared in a continuous process by metering in alkoxysilanes and chlorosilanes in a weight proportion of 60:40 or more to a reaction mixture containing water and non-polar solvent, and continuously removing an organic phase containing organopolysiloxanes from the reaction mixture. | 2019-09-05 |
20190270852 | BLOCK COPOLYMER AND METHOD OF PRODUCING THE SAME, AND METHOD OF PRODUCING STRUCTURE CONTAINING PHASE-SEPARATED STRUCTURE - A block copolymer including a first block consisting of a polymer having a repeating structure of a structural unit (u1) containing no silicon atom, and a second block consisting of a polymer having a repeating structure of a structural unit (u2) containing a silicon atom, the second block containing a block (b21) consisting of a polymer having a repeating structure represented by general formula (u2-1), and a block (b22) consisting of a polymer having a repeating structure of a structural unit (u22) containing a silicon atom, and the block (b22) is positioned between the first block and the block (b21) (wherein R | 2019-09-05 |
20190270853 | METHOD OF PREPARING MONODISPERSED POLYMER POLYOLS - Provided is a method of preparing a polymer polyol including steps of (a) respectively batchwise feeding a polyol and a monomer in a weight ratio of 40 to 60:40 to 60 into a reactor to prepare a mixture; and (b) polymerizing the mixture for 1 to 5 hours to prepare monodispersed particles. | 2019-09-05 |
20190270854 | PROCESS FOR THE MODIFICATION OF HUMINS - Modified humins are prepared by contacting humins with a reactive compound, such as, a carboxylic acid, an acyl halide, a carboxylic anhydride, an olefin, an epoxy-group containing compound and combinations thereof in the presence of an organic aprotic solvent to obtain a humins-containing admixture; maintaining the humins-containing admixture at elevated temperature to achieve a reaction between the humins and the reactive compound, thereby obtaining modified humins; and recovering the modified humins. | 2019-09-05 |
20190270855 | AROMATIC POLYETHER MICROPARTICLES, METHOD FOR PRODUCING CURED RESIN PRODUCT, AND METHOD FOR PRODUCING CARBON-FIBER-REINFORCED COMPOSITE MATERIAL - Aromatic polyether microparticles contain a plurality of particles containing an aromatic polyether in which a content of the particles having a particle diameter equal to or smaller than 50 μm to a total volume of the aromatic polyether microparticles is equal to or higher than 50% by volume. The aromatic polyether microparticles contain phenolic hydroxyl groups in a content equal to or greater than 80 μmol/g. | 2019-09-05 |
20190270856 | SHRINK FILMS AND METHODS FOR MAKING THE SAME - A shrink film includes at least one layer of polyethylene. The layer has a thickness of about 1 mil to about 3 mil. Materials and methods for forming crosslinked shrink films via a blown film extrusion process are described. | 2019-09-05 |
20190270857 | PLANARIZATION COATING FOR FLEXIBLE PRINTED ELECTRONICS - Provided is a planarization coating composition for polyester substrates comprising at least one acrylic polyol, at least one melamine carbamate crosslinker, and optionally at least one acid catalyst, wherein the at least one melamine carbamate is free of formaldehyde. Also provided herein is a method of making a coated polyester substrate, as well as planarization-coated polyester substrates. | 2019-09-05 |
20190270858 | Photoactive Polymer Coatings - Photoactive polymer coatings and methods of making the same are disclosed herein. In some embodiments, a polymer coating comprises a polymer matrix having a porous structure extending throughout the polymer matrix, wherein the porous structure is present at an exposed surface of the polymer coating creating a roughened surface, and a modified support particle disposed within the polymer matrix, wherein the modified support particle includes a substituted phthalocyanine and a support particle. In some embodiments, the substituted phthalocyanine is a halogenated phthalocyanine. | 2019-09-05 |
20190270859 | CROSSLINKED POLYOLEFIN RESIN FOAM - The cross-linked polyolefin resin foam of the present invention is made by cross-linking and foaming a polyolefin resin composition comprising a polyolefin resin-containing resin (A), and a zeolite (B). The polyolefin resin composition includes 0.05 to 10 parts by mass of the zeolite (B) relative to 100 parts by mass of the resin (A) and the average particle diameter of the zeolite (B) is 0.1 to 30 μm. According to the present invention, a cross-linked polyolefin resin foam capable of suppressing the generation of an odor without use of a coloring component such as carbon black can be provided, allowing the foam to be continuously produced using an extruder or the like with high productivity. | 2019-09-05 |
20190270860 | FOAM-MOLDING RESIN COMPOSITION, METHOD FOR PRODUCING FOAM-MOLDED BODY, AND FOAM-MOLDED BODY - A resin composition for foam molding uses a supercritical fluid as a foaming agent. The resin composition includes a thermoplastic resin and an inorganic filler, in which a water absorption rate of the inorganic filler in atmospheric air at a temperature of 25° C. and a relative humidity of 50% is 0.05% or more and 2.0% or less, and a content of the inorganic filler with respect to 100 parts by mass of the resin composition is 1 part by mass or more and 25 parts by mass or less. | 2019-09-05 |
20190270861 | Foam Particles And Foam Particle Molded Body - The present invention is concerned with expanded beads of a block copolymer of a polyethylene block and an ethylene/α-olefin copolymer block, wherein a xylene insoluble fraction (A) of the expanded beads by a hot xylene extraction method is 10 to 70% by weight, and a ratio (A/B) of the xylene insoluble fraction (A) to a xylene insoluble fraction (B) of the expanded beads by a hot xylene extraction method when divided into two equal parts and measured is 1.0 to 1.1, and is able to provide expanded beads with excellent in-mold moldability and an expanded beads molded article with excellent fusion bondability and restorability. | 2019-09-05 |
20190270862 | Repulpable and Recyclable Composite Packaging Articles and Related Methods - A reusable, fiber containing pulp product is described that is highly suited for use in the manufacture of paper products. The reusable, fiber containing pulp product provides a mixture of fibers and small, dense polymer/particle fragments. The polymer/particle fragments within the reusable, fiber containing pulp product have a size range and density that facilitates efficient removal of the polymer/particle fragments using pressure screens. | 2019-09-05 |
20190270863 | Polyisoprene Latex Graphene Composites and Methods of Making Them - The present Invention' relates to a method of preparing reduced grapheme oxide, Incorporation of the adduced graphene oxide into polyisoprene latex to provide a polyisoprene latex graphene composite and elastomerk articles prepared using the polyisoprene latex-graphene composite. In particular, the reduction of-graphene oxide is accomplished without the use of strong reducing agents and organic solvents and incorporation of die reduced graphene oxide into polyisoprene latex Is accomplished using room temperature latex mixing method or hot maturation. The resultant composite exhibits good colloid stability and polyisoprene latex films produced from the composite exhibit good mechanical properties with improved ageing resistance. | 2019-09-05 |